Neoadjuvant chemotherapy (NAC) is currently administered to patients with locally advanced breast cancers (BC), to BC of poor prognosis (triple negative and HER2- positive cancers, or BC with nodal involvement and/or high proliferation rates), or to early stage BC that have an indication of systemic therapy [1]. This evidence concerns the gene ERBB2 and breast cancer.